3 active not recruiting, 2 recruiting, 1 completed, 1 not yet recruiting. 6 Phase 1, 1 Early Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Active not recruiting 2, Completed 1, Not yet recruiting 1, Recruiting 1, Terminated 1 |
| Early Phase 1 | 1 | Active not recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow AZD1390: new trials by email Literature Review of AZD1390 trials Research Report on AZD1390
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Human ADME Study of [14C]-AZD1390 AZD1390 - Advanced Solid Malignancies | Phase 1 | Not yet recruiting | AstraZeneca | 8 | 2026-06-30 | 2026-06-12 |
| Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma ATM Kinase Inhibitor AZD1390, Biospecimen Collection, Magnetic Resonance Imaging - Childhood Astrocytoma, Childhood Diffuse Intrinsic Pontine Glioma | Phase 1 | Active not recruiting | Children's Oncology Group | 54 | 2025-06-18 | 2026-08-17 |
| A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer AZD1390, Stereotactic Body Radiotherapy - Solid Tumor, Metastatic Solid Tumor | Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 54 | 2023-05-17 | 2026-05-18 |
| Sarcomas and DDR-Inhibition; a Combined Modality Study AZD1390 + radiotherapy, AZD1390 + durvlaumab + radiotherapy - Soft Tissue Sarcoma Adult | Phase 1 | Terminated | The Netherlands Cancer Institute | 12 | 2022-07-18 | 2026-01-23 |
| AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients AZD1390 - Glioblastoma, Glioma | Early Phase 1 | Active not recruiting | Nader Sanai | 97 | 2022-05-27 | 2026-03-09 |
| A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC Radiotherapy, Olaparib Oral Tablet [Lynparza], AZD1390 - Non Small Cell Lung Cancer | Phase 1 | Recruiting | University of Leeds | 200 | 2021-03-17 | 2025-12-19 |
| A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma Temozolomide, Lomustine, Regorafenib - Glioblastoma | Phase 2 / Phase 3 | Recruiting | Global Coalition for Adaptive Research | 2250 | 2019-07-30 | 2026-10-23 |
| A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer Radiation Therapy, AZD1390 - Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme | Phase 1 | Completed | AstraZeneca | 159 | 2018-04-02 | 2026-10-15 |
Glioblastoma (4) · Astrocytoma (1) · Brain Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Glioma (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Inhibition, Psychological (1) · Meningeal Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Recurrence (1) · Sarcoma (1)
AstraZeneca (2) · Children's Oncology Group (1) · Global Coalition for Adaptive Research (1) · Memorial Sloan Kettering Cancer Center (1) · Nader Sanai (1) · The Netherlands Cancer Institute (1) · University of Leeds (1)
United States (5) · United Kingdom (3) · Australia (1) · Canada (1) · France (1) · Germany (1) · Japan (1) · Netherlands (1) · Switzerland (1)
Alastair Greystoke, MB ChB, MSc, PhD (1) · Anthony Chalmers (1) · Brandon Imber (1) · Corinne Faivre-Finn, MD, PhD (1) · Daniel Higginson, MD (1) · Deborah Forst (1) · Erin K Barr (1) · Jan Drappatz (1) · Kazuhiko Mishima (1) · Louise Murray (1) · Mariza Daras (1) · Nader Sanai, MD (1) · Patrick Wen (1) · Rajesh Jena (1) · Rick Haas, MD Prof (1)
PMID 36446040, PMID 38773224, PMID 41980234
2017 (1), UM1CA228823 (1)